AlectorALEC
Market Cap: 626M
About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Employees: 244
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
8,400% more call options, than puts
Call options by funds: $425K | Put options by funds: $5K
59% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 37
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
7% more funds holding
Funds holding: 145 [Q4 2023] → 155 (+10) [Q1 2024]
1.37% more ownership
Funds ownership: 75.96% [Q4 2023] → 77.32% (+1.37%) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]
13% less capital invested
Capital invested by funds: $510M [Q4 2023] → $446M (-$64.3M) [Q1 2024]
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
HC Wainwright & Co. Andrew Fein | 439%upside $35 | Buy Reiterated | 20 Jun 2024 |
HC Wainwright & Co. Andrew Fein | 439%upside $35 | Buy Maintained | 9 May 2024 |
HC Wainwright & Co. Andrew Fein | 532%upside $41 | Buy Reiterated | 28 Feb 2024 |